We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Settlement over Amgen $28bn acquisition shows the antitrust chief still won concessions to protect consumers
Federal Trade Commission said it secured concessions from pharma company to resolve its competition concerns
Expensive medicines made by Pfizer, J&J and Merck selected for talks in biggest shake-up in decades
Antitrust challenge may force big pharma groups to rethink ‘pure play’ business models
Development chief raises worry over innovation after FTC sues to block Amgen-Horizon deal
The US trust buster’s opposition to the tie-up focuses on so-called pharmacy benefit managers
Leonard Schleifer supportive of FTC’s lawsuit against takeover of Horizon Therapeutics
Plus, boutique investment bank Raine pockets a huge fee and Deutsche Bank’s chair makes his mark
Ukraine says it has blocked an unprecedented barrage of Russian missiles over Kyiv
US regulator sues to block takeover of biotech group Horizon Therapeutics
Amgen to launch ‘biosimilar’ version of medicine that has generated $200bn in sales since launch
Eli Lilly, Amgen, Pfizer and Regeneron follow Novo Nordisk into obesity treatments worth billions
The strategic logic of buying Horizon is hard to fault. But good assets do not come cheap
California-based biotech wins three-way race to secure new drugs pipeline
Drugmakers seek to replenish pharmaceuticals pipelines amid broader slowdown in transactions
The pursuit of novel mechanisms in fighting diseases is paying dividends
Deal helps advance Bristol-Myers Squibb’s $90bn takeover of rival biotech giant Celgene
Move comes after some patients on the trials showed a worsening in cognitive function
Amgen, Merck and Eli Lilly say Trump administration’s move infringes on free speech
Researchers may have found way to target gene implicated in cancers
California-based group acquires 3 per cent stake in UK sequencing company
UK Edition
